Castleark Management’s Ascendis Pharma A/S ASND Stock Holding History

Castleark Management’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$15.5M	Buy	67,616 +1,280	+2%	+$287K	0.51%	38
2025 Q4	$14.1M	Buy	66,336 +23,680	+56%	+$4.89M	0.42%	44
2025 Q3	$8.48M	Buy	+42,656	New	+$7.96M	0.24%	81
2021 Q3	–	Sell	-3,095	Closed	-$407K	–	331
2021 Q2	$407K	Hold	3,095	–	–	0.01%	262
2021 Q1	$399K	Sell	3,095 -800	-21%	-$122K	0.01%	268
2020 Q4	$650K	Hold	3,895	–	–	0.02%	270
2020 Q3	$601K	Hold	3,895	–	–	0.02%	264
2020 Q2	$576K	Hold	3,895	–	–	0.03%	252
2020 Q1	$439K	Sell	3,895 -400	-9%	-$52K	0.03%	238
2019 Q4	$598K	Sell	4,295 -435	-9%	-$48.3K	0.02%	269
2019 Q3	$456K	Buy	4,730 +630	+15%	+$70.3K	0.02%	294
2019 Q2	$472K	Buy	+4,100	New	+$491K	0.02%	294

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Castleark Management's ASND Position: Q1 2026 in Review

Castleark Management increased its Ascendis Pharma A/S (ASND) stake by 1.9% in Q1 2026, buying an estimated $287K and bringing the position to 67,616 shares worth $15.5M. The position accounts for 0.51% of the portfolio, ranked #38.

Castleark Management first reported a position in ASND in Q2 2019 and has held it in 12 quarters since. 273 funds tracked by Wall St. Rank hold ASND as of Q1 2026.

Castleark Management held 67,616 shares of Ascendis Pharma A/S worth $15.5M as of Q1 2026.
Castleark Management bought 1,280 Ascendis Pharma A/S shares in Q1 2026, an estimated $287K.
Ascendis Pharma A/S made up 0.51% of Castleark Management's portfolio in Q1 2026, its #38 holding.
Castleark Management first reported a position in Ascendis Pharma A/S in Q2 2019 and has held it in 12 quarters since.
273 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2026.

Based on Castleark Management's 13F filing for Q1 2026, filed 15 May 2026.